Zifivax Vaccine Shows High Efficacy, Use Not Confirmed
Translator
Editor
10 October 2021 23:28 WIB
TEMPO.CO, Jakarta - Clinical trial of the Zifivax vaccine from China in Indonesia has been completed with an efficacy rate against Covid-19 at around 81 to 87 percent. However, so far, there has been no information concerning the use of the vaccine in Indonesia. "The Health Ministry can answer that," said the vaccine's main researcher Rodman Tarian from the Padjajaran University Medical Faculty on Sunday, October 10, 2021.
As a researcher, he claimed that he has no information concerning the plan to use the Zifivax vaccine in Indonesia. Rodman said that the decision to use the vaccine in mass vaccination or private vaccination will be made by the sponsors and the government. The vaccin was originally developed by Anhui Zhifei Longcom Biopharmaceutical in China.
Previously, it was reported that the Zifivax vaccine had received the permit for emergency services during the Covid-19 pandemic from the Food and Drugs Supervisory Agency (BPOM). Rodman said that Zifivax can be used as primary vaccine and as booster.
"With three doses of recombinant vaccine hopefully it can last for one year," Rodman said.
According to Rodman in the Padjajaran University's website, injecting three doses of vaccine is better than two times to increase the patient's body immunity. In the meantime, the reseacher team continues to observe the potential candidate of students
The total number of volunteers in Bandung and Jakarta reached up to 2,000 people with an age range of 18 to 60 years-old.
"The vaccine's efficacy for people aging between 18 to 59 years old is at 81.51 percent, meanwhile for people above 60 years old, the efficacy rate is 87.58 percent,"
In addition the vaccine is said to be a cure of the more severe Covid-19 variants,one of which is the Delta variant.
"The Zifivax vaccine's efficacy against the Delta variant is 77.47 percent," Rodman said.
ANWAR SISWADI (CONTRIBUTOR)
